Effects of treatment with polysulfated glycosaminoglycan on serum cartilage oligomeric matrix protein and C-reactive protein concentrations, serum matrix metalloproteinase-2 and -9 activities, and lameness in dogs with osteoarthritis.
OBJECTIVE
To investigate the effects of polysulfated glycosaminoglycan (PSGAG) treatment on serum cartilage oligomeric matrix protein (COMP) concentration, matrix metal-loproteinase-2 (MMP-2) and -9 (MMP-9) activities, C-reactive protein (CRP) concentration, and lameness scores in dogs with osteoarthritis.


METHODS
16 dogs with osteoarthritis and 5 clinically normal dogs.


METHODS
Dogs with osteoarthritis had a history of chronic lameness, and osteophytes were observed on radiographic evaluation of the affected joint. Polysulfated glycosaminoglycan was administered IM twice a week for a total of 8 treatments to all dogs with osteoarthritis and to clinically normal control dogs.


RESULTS
Lameness scores after PSGAG treatment in osteoarthritic dogs improved in 12 of the 16 dogs. Serum COMP concentrations in osteoarthritic dogs were significantly higher than in control dogs before treatment. Lameness scores in osteoarthritic dogs decreased significantly after treatment, compared with before treatment. Lameness scores of 9 dogs with hind limb lameness improved significantly after treatment; these dogs had corresponding decreases in serum COMP concentrations. After treatment, serum COMP concentrations and lameness scores of 7 dogs with forelimb lameness remained high and were significantly higher than those of dogs with hind limb lameness. Serum MMP-9 activities of dogs with forelimb lameness were significantly higher than in dogs with hind limb lameness after treatment.


CONCLUSIONS
IM administration of PSGAG inhibited COMP degradation in dogs with osteoarthritis. Results indicate that decreases in serum COMP concentrations might be related to improvement in lameness after PSGAG treatment.
Laboratory of Veterinary Surgery, Department of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-0065, Japan.
Makoto
M
Fujiki
Joe
J
Shineha
Kazuto
K
Yamanokuchi
Kazuhiro
K
Misumi
Hiroshi
H
Sakamoto
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000378:metabolism*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D016326:Extracellular Matrix Proteins / Q000097:blood*; D006023:Glycoproteins / Q000097:blood*; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D007794:Lameness, Animal / Q000188:drug therapy; D064235:Matrilin Proteins; D020778:Matrix Metalloproteinase 2 / Q000097:blood* / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000097:blood* / Q000378:metabolism; D010003:Osteoarthritis / Q000188:drug therapy / Q000662:veterinary*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016326:Extracellular Matrix Proteins; D006023:Glycoproteins; D006025:Glycosaminoglycans; D064235:Matrilin Proteins; C013786:A73025; D002097:C-Reactive Protein; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9